Disulfide-Bridged Chitosan-Eudragit S-100 Nanoparticles for Colorectal Cancer

Covalently bonded Eudragit S-100 (EU) and Chitosan (CS) based colon-specific nanoparticles (CSE NPs) were fabricated as drug carriers for treating colorectal cancers through oral administration. Thiolation of EU and CS prevents the usage of cross linking agent. This gives an advantage over the shortcomings of existing EU & CS based delivery systems that are associated with large sized nanoparticles with a broad range of size distribution. Paclitaxel (PTX) loaded CSE NPs presented an efficacy of 8-10% after 48h of treatment on HCT 116 cell line signifying uniform distribution of drug inside the cells. About 66 % accumulation of cell population was observed in G2/M phase for PTX loaded CSE NPs indicating arrest of cell division during mitotic phase. Biodistribution studies on male Balb/C mice demonstrated retention of CSE NPs in colon region up to 24h post-oral administration. These findings confer a convenient and effective way for preparing CS & EU based drug delivery system with sustained release and tar...